Navigation Links
WuXi PharmaTech Provides Update of 2011 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
Date:1/9/2012

SHANGHAI, Jan. 9, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, today announced that it will present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 4:30 p.m. Pacific Standard Time and updated its 2011 financial guidance. Based on preliminary, unaudited results, WuXi expects to slightly exceed the top end of its previous guidance for 2011 total net revenues of $402-406 million and to meet the remainder of the 2011 financial guidance found in its third-quarter 2011 earnings release.

WuXi plans to report its audited fourth-quarter and full-year 2011 financial results and to provide 2012 financial guidance in March 2012.

For more information, please contact:

WuXi PharmaTech (Cayman) Inc.
Ronald Aldridge (for investors)
Director of Investor Relations
Tel: +1-201-585-2048
Email: ir@wuxiapptec.com

Stephanie Liu (for the media)
WuXi PharmaTech (Cayman) Inc.
Tel: +86-21-5046-4362
Email: pr@wuxiapptec.com

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including those with respect to our financial guidance for full-year 2011 and prospects generally, are based on our preliminary unaudited results and are subject to the completion of our 2011 audit. Our actual results and financial condition and other circumstances may differ, possibly materially, from the antic
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
2. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
3. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
6. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
7. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
8. WuXi PharmaTech Announces First-Quarter 2010 Results
9. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
10. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
11. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. ... inoperable solid tumor cancers, announced today that CEO Linda ... Phacilitate Immunotherapy Forum in Washington D.C. ... on January 26 at 10:30 a.m. EST at the Grand ...
(Date:1/23/2015)...  Pete Rose, baseball,s all-time hits leader, is the new spokesperson ... Ducere Pharma has announced. "Pete,s a Hall of ... him on board with Myoflex," said Ducere Pharma Chief Executive ... who is known across all generations. The passion and intensity ...
(Date:1/23/2015)... 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) ... "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with the ... provides an update for shareholders detailing why a "YES" vote ... Dear Shareholders, As we reflect upon the ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... - Roche today announced,results of a small study ... (peginterferon alfa-2b),and ribavirin due to adverse events within ... weeks of treatment with PEGASYS(R),(peginterferon alfa-2a) and ribavirin. ... go on and complete a full course of,treatment ...
... ACCEPTED FOR REVIEW BY,FDA- , BASEL, Switzerland and ... SPPN) today welcomed the significant new results from,clinical ... the 22nd Annual Scientific Meeting,and Exposition of the ... These results confirm the favourable safety and,efficacy profile, ...
Cached Medicine Technology:Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 2Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 3Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 4Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 5Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 2New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 3New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 4New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 5New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 7New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 8New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 9New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 10New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 11
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... breast cancer trials has confirmed that combination treatment with ... women with operable HER-2 positive breast cancer. ... University of Athens reported the results of a meta-analysis ... breast cancer was amenable to surgery. ,All ...
... to be safe to normal tissue but deadly to cancer ... said today at the ESMO Conference Lugano (ECLU), Switzerland. ... simplex virus modified so that it selectively replicates in virus ... replicate in normal, healthy cells, so our hope is that ...
... other people were slightly hurt Saturday as thousands of Spaniards ... bullrun. ,The festival involves copious amounts of ... the streets and hundreds of people are chased along an ... later staged. ,Fourteen people have died in the ...
... Barely 24 hours after it advised parents to seek urgent ... illness , the West Australian Health Department said there ... of three Perth children younger than five past week - ... had triggered off panic. , ,The state communicable ...
... people on Saturday after violence marred a Gay Pride march ... ,Organisers said more than 20 marchers had been the ... two needing medical treatment," Marko Jurcic, one of the organisers, ... one of the groups attacked, but was unhurt, Jurcic said. ...
... is no such thing as a safe suntan. The Commission ... per cent sun protection from bottles of sun cream. , ... a common standard of information would end consumer ... up to 1,800 Britons a year. ,A recent ...
Cached Medicine News:Health News:Combination of Tratuzumab and Chemotherapy Yields Better Results for Breast Cancer 2Health News:New Cancer Fighting Virus 2Health News:No Flu Outbreak Here , West Australians Told 2Health News:European Commission Seeks To Dispel The Darkness Out Of Sunscreens 2
... used screening test for determining the presence ... branded system is considered the manual standard, ... other system meets defined NCCLS/ICSH guidelines designed ... systems are also available for pediatric applications, ...
The HEMOCHRON Signature Elite offers state-of-the-art features like barcode scanning, internal Electronic Quality Control (EQC), QC Lockout and alphanumeric data entry for Patient Identification (PID...
Inquire...
The Minilyser offers a combination of three well proven instruments for fully automated processing of microplates. The Minilyser is the optimal fully automated ELISA and EIA equipment for laboratorie...
Medicine Products: